Development and characterization of monoclonal antibodies against human epidermal growth factor receptor in Balb/c mice

Human Antibodies

Volumn 18, Issue 1-2, 2009, Pages 11-16

  Baradaran, Behzad ^a   Hosseini, Ahmad Zavaran ^a   Majidi, Jafar ^a,b   Farajnia, Safar ^b   Barar, Jaleh ^c   Saraf, Zohair Hassan ^a   Abdolalizadeh, Jalal ^b   Omidi, Yadollah ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

A431 cells; Cancer; EGFR; Monoclonal antibody

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MACROGOL; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; ASCITES FLUID; CANCER DIAGNOSIS; CANCER THERAPY; CELL FUSION; CLONE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYBRIDOMA CELL CULTURE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUPERNATANT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYBRIDOMAS; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 67249101192     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2009-0195     Document Type: Article

References (19)

1. G.P. Adams and L.M. Weiner, Monoclonal antibody therapy of cancer, Nature Biotechnology 23 (2005), 1147-1157.
2. J. Azim and A.K. Ganti, Targeted therapy in advanced non- small cell lung cancer (NSCLC): Where do we stand? Cancer Treatment Review 32 (2006), 630-636.
3. B. Baradaran, J. Majidi, Z.M. Hassan and J. Abdolalizadeh, Large scale production and characterization of anti- human IgG monoclonal antibody in peritoneum of Balb/c mice, Am J Biochem Biotechnol 1 (2006), 190-193.
4. A.T. Baron, J.M. Lafky, D.C. Connolly, J. Peoples, D.J. O'Kane, V.J. Suman, C.H. Boardman, K.C. Podratz and N.J. Maihle, A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera, Journal of Immunological Methods 219 (1998), 23-43.
5. J. Barton, G. Blackledge and A. Wakeling, Growth factors and their receptors: New targets for prostate cancer therapy, Urology 58 (2001), 114-122.
6. F. Ciardiello, R. Bianco, V. Damiano, G. Fontanini, R. Ca- puto, G. Pomatico, S. De Placido, A.R. Bianco, J. Mendelsohn and G. Tortora, Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells, Clinical Cancer Research 6 (2000), 3739-3747.
7. F. Ciardiello and G. Tortora, A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor, Clinical Cancer Research 7 (2001), 2958-2970.
8. E.W. Cowen, Epidermal growth factor receptor inhibitors: A new era of drug reactions in a new era of cancer therapy, Journal of the American Academy of Dermatology 56 (2007), 514-517.
9. Helmout Modjtahedi, Monoclonal Antibodies as Therapeutic Agents: Advances and Challenges, IJI 2 (2005), 3-20.
10. JOSE' BASELGA, Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy, The Oncologist 7 (2002), 2-8.
11. A.A. Jungbluth, E. Stockert, H.J.S. Huang, V.P. Collins, K. Coplan, K. Iversen, D. Kolb, T.J. Johns, A.M. Scott, W.J. Gul- lick, G. Ritter, L. Cohen, M.J. Scanlan, W.K. Cavanee and L.J. Old, A monoclonal antibody recognizing human cancers with amplification/ overexpression of the human epidermal growth factor receptor, Proceedings of the National Academy of Sciences of the United States of America 100 (2003), 639-644.
12. G. Kohler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature 256 (1975), 495-497.
13. N.J. Maihle, A.T. Baron, B.A. Barrette, C.H. Boardman, T.A. Christensen, E.M. Cora, J.M. Faupel-Badger, T. Greenwood, S.C. Juneja, J.M. Lafky, H. Lee, J.L. Reiter and K.C. Po- dratz, EGF/ErbB receptor family in ovarian cancer, Cancer Treatment and Research 107 (2002), 247-258.
14. C. Mamot and C. Rochlitz, Targeting the epidermal growth factor receptor (EGFR) - A new therapeutic option in oncology? Swiss Medical Weekly 136 (2006), 4-12.
15. J. Mendelsohn, Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy, Clinical Cancer Research 3 (1997), 2703-2707.
16. J. Mendelsohn, Blockade of receptors for growth factors: An anticancer therapy - The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture, Clinical Cancer Research 6 (2000), 747-753.
17. M.F. Press and H.J. Lenz, EGFR, HER2 and VEGF pathways: Validated targets for cancer treatment, Drugs 67 (2007), 2045-2075.
18. A.M. Scott, F.T. Lee, N. Tebbutt, R. Herbertson, S.S. Gill, Z. Liu, E. Skrinos, C. Murone, T.H. Saunder, B. Chappell, A.T. Papenfuss, A.M.T. Poon, W. Hopkins, F.E. Smyth, D. MacGregor, L.M. Cher, A.A. Jungbluth, M.W. Brechbiel, R. Murphy, A.W. Burgess, E.W. Hoffman, T.G. Johns and L.J. Old, A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors, Proceedings ofthe National Academy ofSciences of the United States of America 104 (2007), 4071-4076.
19. X.D. Yang, X.C. Jia, J.R.F. Corvalan, P. Wang and C.G. Davis, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy, Critical Reviews in Oncology/Hematology 38 (2001), 17-23.